In This Article:
-
Preliminary Q1 2025 Revenue: $37.9 million, up 28% year-over-year, down 6% sequentially from Q4 2024.
-
LDD Sales: 73 units sold, up 11% year-over-year, down 12% sequentially from Q4 2024.
-
LDD Installed Base: 1,044 units, up 43% year-over-year, up 8% sequentially from Q4 2024.
-
LAL Sales: 27,579 units, up 36% year-over-year, down 5% sequentially from Q4 2024.
-
Revised 2025 Revenue Guidance: $160 million to $175 million, down from previous $185 million to $197 million.
-
Gross Margin Guidance: Unchanged at 71% to 73%.
-
Revised Operating Expense Guidance: $150 million to $160 million, down from previous $165 million to $170 million.
-
Stock-Based Compensation Expense: Revised to $27 million to $30 million, up from previous $22 million to $25 million.
Release Date: April 03, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
RxSight Inc (NASDAQ:RXST) reported a 28% increase in preliminary first-quarter revenue compared to the same period last year.
-
The company sold 73 Light Delivery Devices (LDDs) in Q1, marking an 11% increase from the previous year.
-
RxSight Inc (NASDAQ:RXST) achieved a 36% increase in Light Adjustable Lenses (LALs) sales compared to Q1 2024.
-
The company received European regulatory approval for its LDD and LAL, expanding its potential market reach.
-
Customer satisfaction is at an all-time high of 97%, indicating strong acceptance of RxSight's adjustable technology.
Negative Points
-
RxSight Inc (NASDAQ:RXST) revised its full-year revenue guidance downward from $185-$197 million to $160-$175 million.
-
The company experienced a sequential 6% decline in revenue from Q4 2024 to Q1 2025.
-
There was a notable decline in LALs per LDD per month, indicating reduced utilization rates.
-
The premium IOL market has softened, impacting RxSight Inc (NASDAQ:RXST)'s sales and growth projections.
-
Macroeconomic factors, including declines in the S&P and NASDAQ, have negatively affected consumer sentiment and decision-making for premium IOL procedures.
Q & A Highlights
Q: Can you elaborate on the underlying assumptions for guidance, particularly regarding the productivity of LALs per LDD? A: Shelley Thunen, CFO: The guidance reflects a change in the number of LALs we expect to sell, offset by strong LDD sales. Typically, we see sequential growth in LALs per LDD, but given current economic uncertainties, we're cautious about predicting typical seasonality until we see second-quarter results.
Q: How do you prioritize the factors that led to the Q1 miss, and what is transient versus more permanent? A: Ron Kurtz, CEO: The Q1 miss was due to a confluence of factors, including macroeconomic changes and sequential product launches by competitors. These are largely transitory. The macro environment is complex, but we hope for improvement. The product launches are planned years in advance and are unusual in their frequency.